On September 22, LEADS BIOLABS-B fell 5.59% in regular trading, trading at 53.7 HKD/share, with turnover of approximately 22.15 million HKD, as profit-taking pressure emerged following a string of positive catalysts.
On the news front, the company's share incentive platform Nanjing Lizhi sold approximately 859,100 shares on the open market on September 15 at an average price of 63.69 HKD per share, totaling around 54.72 million HKD. The disposal reduced the platform's stake from 15.37% to 14.93%. The sale was executed on behalf of individual employees exercising their vested shares.
While the company announced on September 21 that its pivotal Phase IIb study of Opamtistomig monotherapy in advanced extrapulmonary neuroendocrine carcinoma was selected as a Late-Breaking Abstract at ESMO 2026 with a proffered oral presentation — a significant milestone — the stock had already rallied sharply in prior sessions. Morgan Stanley recently upgraded the stock to Overweight with a target price of 93 HKD, and strong Phase II WCLC data showing a 71.0% ORR in first-line NSCLC had driven consecutive gains, setting the stage for near-term profit-taking.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments